Technical Analysis for HOWL - Werewolf Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Volume Surge | Other | -3.69% | |
Inside Day | Range Contraction | -3.69% | |
Wide Bands | Range Expansion | -3.69% | |
Wide Bands | Range Expansion | -6.37% | |
Oversold Stochastic | Weakness | -6.37% | |
Jack-in-the-Box Bearish | Bearish Swing Setup | 0.43% | |
Inside Day | Range Contraction | 0.43% | |
Wide Bands | Range Expansion | 0.43% |
Alert | Time |
---|---|
Down 10% | about 9 hours ago |
Down 5% | about 9 hours ago |
Down 3% | about 9 hours ago |
Fell Below Previous Day's Low | about 9 hours ago |
60 Minute Opening Range Breakdown | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/08/2024
Werewolf Therapeutics, Inc. Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.1939 |
52 Week Low | 1.5735 |
Average Volume | 316,553 |
200-Day Moving Average | 4.24 |
50-Day Moving Average | 4.52 |
20-Day Moving Average | 3.01 |
10-Day Moving Average | 2.62 |
Average True Range | 0.43 |
RSI (14) | 28.06 |
ADX | 36.71 |
+DI | 9.64 |
-DI | 30.09 |
Chandelier Exit (Long, 3 ATRs) | 4.44 |
Chandelier Exit (Short, 3 ATRs) | 3.25 |
Upper Bollinger Bands | 3.96 |
Lower Bollinger Band | 2.06 |
Percent B (%b) | 0.15 |
BandWidth | 63.31 |
MACD Line | -0.62 |
MACD Signal Line | -0.62 |
MACD Histogram | 0.0034 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.88 | ||||
Resistance 3 (R3) | 2.88 | 2.71 | 2.79 | ||
Resistance 2 (R2) | 2.71 | 2.57 | 2.71 | 2.76 | |
Resistance 1 (R1) | 2.53 | 2.49 | 2.44 | 2.53 | 2.73 |
Pivot Point | 2.35 | 2.35 | 2.31 | 2.35 | 2.35 |
Support 1 (S1) | 2.17 | 2.22 | 2.09 | 2.17 | 1.97 |
Support 2 (S2) | 2.00 | 2.13 | 2.00 | 1.94 | |
Support 3 (S3) | 1.82 | 2.00 | 1.91 | ||
Support 4 (S4) | 1.82 |